Lysophosphatidylcholine-biomarker of Metformin action: studied using UPLC/MS/MS

被引：15

作者：

Cai, Shuang ^{[1
,2
]}

Huo, Taoguang ^{[1
]}

Li, Ning ^{[1
]}

Xiong, Zhili ^{[1
]}

Li, Famei ^{[1
]}

机构：

[1] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China

[2] China Med Univ, Affiliated Hosp 1, Shenyang 110001, Peoples R China

来源：

BIOMEDICAL CHROMATOGRAPHY | 2009年 / 23卷 / 07期

关键词：

UPLC/MS/MS; metabonomics; metformin; biomarkers; lysophosphatidylcholine; MASS-SPECTROMETRY; METABONOMICS; LIVER; NMR;

D O I：

10.1002/bmc.1185

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

An UPLC/MS/MS based metabonomic method was developed and applied to the elucidation of biomarker of metformin action. The plasma metabolite profiling in healthy volunteers before and after per os metformin was determined with UPLC/MS/MS and analyzed by using multivariate statistics. Significant difference in endogenous metabolite profiles was revealed before and after administration of metformin. Four biomarkers found were lysophosphatidylcholines (LPCs), and their structures were tentatively identified to be 16:0 LPC, 18:0 LPC, 18:1 LPC and 18:2 LPC according to the molecular ions information and corresponding fragments of product ion scan. Lysophosphatidylcholine in blood may be involved in metformin treatment. Copyright (C) 2009 John Wiley & Sons, Ltd.

引用

页码：782 / 786

页数：5

共 18 条

[1] NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition [J].

Bollard, ME ;

Stanley, EG ;

Lindon, JC ;

Nicholson, JK ;

Holmes, E .

NMR IN BIOMEDICINE, 2005, 18 (03) :143-162

[2] A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition [J].

Castro-Perez, J ;

Plumb, R ;

Liang, L ;

Yang, E .

RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2005, 19 (06) :798-804

[3] Metabonomic study of aristolochic acid-induced nephrotoxicity in rats [J].

Chen, MJ ;

Su, MM ;

Zhao, LP ;

Jiang, J ;

Liu, P ;

Cheng, JY ;

Lai, YJ ;

Liu, YM ;

Jia, W .

JOURNAL OF PROTEOME RESEARCH, 2006, 5 (04) :995-1002

[4]

Cusi K, 1998, DIABETES REV, V6, P89

[5] Within-day reproducibility of an HPLC-MS-Based method for metabonomic analysis: Application to human urine [J].

Gika, Helen G. ;

Theodoridis, Georgios A. ;

Wingate, Julia E. ;

Wilson, Ian D. .

JOURNAL OF PROTEOME RESEARCH, 2007, 6 (08) :3291-3303

[6] Metformin: An update [J].

Kirpichnikov, D ;

McFarlane, SI ;

Sowers, JR .

ANNALS OF INTERNAL MEDICINE, 2002, 137 (01) :25-33

[7] Oral antidiabetic agents - Current role in type 2 diabetes mellitus [J].

Krentz, AJ ;

Bailey, CJ .

DRUGS, 2005, 65 (03) :385-411

[8] The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements [J].

Lindon, JC ;

Keun, HC ;

Ebbels, TMD ;

Pearce, JMT ;

Holmes, E ;

Nicholson, JK .

PHARMACOGENOMICS, 2005, 6 (07) :691-699

[9] Metformin in polycystic ovary syndrome: systematic review and meta-analysis [J].

Lord, JM ;

Flight, IHK ;

Norman, RJ .

BRITISH MEDICAL JOURNAL, 2003, 327 (7421) :951-955

[10] Metabonomics: a platform for studying drug toxicity and gene function [J].

Nicholson, JK ;

Connelly, J ;

Lindon, JC ;

Holmes, E .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (02) :153-161

← 1 2 →